Neuronal nicotinic acetylcholine receptor subunit alpha-7 (α7 nAChR)

The neuronal nicotinic acetylcholine receptor subunit alpha-7 (**α7 nAChR**) is a ligand-gated ion channel predominantly found in the central nervous system, as well as in peripheral tissues such as the spleen and lymphocytes[1][2][3][6]. It assembles as a homopentamer (five α7 subunits), forming a Cys-loop receptor highly permeable to calcium ions and characterized by rapid desensitization kinetics[1][5][6]. α7 nAChR plays crucial roles in synaptic transmission, modulating neurotransmitter release, learning, memory, attention, and neuroprotection[2][6]. It is also implicated in the cholinergic anti-inflammatory pathway, influencing immune responses[1][2]. Alterations in α7 nAChR function and expression have been linked to neurodegenerative diseases (including Alzheimer's), schizophrenia, stroke, inflammation, and certain cancers through effects on cell proliferation, apoptosis, and angiogenesis[2][6]. Drugs targeting α7 nAChR act as agonists, antagonists, or allosteric modulators, and are under investigation for therapeutic use in cognitive disorders, neuroprotection, smoking cessation, and anti-inflammatory interventions; notable examples include nicotine, varenicline, EVP-6124, and PNU-120596[2][3][6]. Therapeutic targeting of α7 nAChR poses challenges, such as rapid receptor desensitization and potential pro-cancer signaling, requiring careful consideration in drug development[2][6].

Other names

alpha-7 nicotinic receptorα7 receptorCHRNA7 (gene)α7-nAChR

Agonists increase cation (notably Ca²⁺) influx, depolarizing neurons and enhancing synaptic transmission; Partial agonists modulate the receptor’s activation leading to altered neurotransmitter release; Positive allosteric modulators increase receptor response to agonists; Antagonists (e.g., α-bungarotoxin) block agonist binding and ion channel opening